David Wendler

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6873740/publications.pdf

Version: 2024-02-01

140 papers 6,071 citations

35 h-index 76900 **74** g-index

142 all docs

142 docs citations

times ranked

142

5748 citing authors

#	Article	IF	CITATIONS
1	The Accuracy of Surrogate Decision Makers. Archives of Internal Medicine, 2006, 166, 493.	3.8	796
2	Are Racial and Ethnic Minorities Less Willing to Participate in Health Research?. PLoS Medicine, 2005, 3, e19.	8.4	652
3	Systematic Review: The Effect on Surrogates of Making Treatment Decisions for Others. Annals of Internal Medicine, 2011, 154, 336.	3.9	519
4	How Do Institutional Review Boards Apply the Federal Risk and Benefit Standards for Pediatric Research?. JAMA - Journal of the American Medical Association, 2004, 291, 476.	7.4	246
5	Broad Consent for Research With Biological Samples: Workshop Conclusions. American Journal of Bioethics, 2015, 15, 34-42.	0.9	221
6	Reframing Consent for Clinical Research: A Function-Based Approach. American Journal of Bioethics, 2017, 17, 3-11.	0.9	176
7	One-time general consent for research on biological samples. BMJ: British Medical Journal, 2006, 332, 544-547.	2.3	173
8	Patients' and Parents' Needs, Attitudes, and Perceptions About Early Palliative Care Integration in Pediatric Oncology. JAMA Oncology, 2017, 3, 1214.	7.1	146
9	Moral Standards for Research in Developing Countries from "Reasonable Availability" to "Fair Benefits". Hastings Center Report, 2004, 34, 17.	1.0	137
10	Deception in Research on the Placebo Effect. PLoS Medicine, 2005, 2, e262.	8.4	133
11	Screening for, Monitoring, and Treatment of Chronic Kidney Disease Stages 1 to 3: A Systematic Review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline. Annals of Internal Medicine, 2012, 156, 570.	3.9	131
12	Quantifying the Federal Minimal Risk Standard. JAMA - Journal of the American Medical Association, 2005, 294, 826.	7.4	113
13	Research With Stored Biological Samples. Archives of Internal Medicine, 2005, 165, 652.	3.8	97
14	The ethics of paying for children's participation in research. Journal of Pediatrics, 2002, 141, 166-171.	1.8	95
15	Evaluating the Risks of Clinical Research. JAMA - Journal of the American Medical Association, 2010, 304, 1472.	7.4	89
16	Deception in the Pursuit of Science. Archives of Internal Medicine, 2004, 164, 597.	3.8	82
17	The Standard of Care Debate: Can Research in Developing Countries Be Both Ethical and Responsive to Those Countries' Health Needs?. American Journal of Public Health, 2004, 94, 923-928.	2.7	79
18	The 50th Anniversary of the Declaration of Helsinki. JAMA - Journal of the American Medical Association, 2013, 310, 2143.	7.4	74

#	Article	IF	CITATIONS
19	Why Patients Continue to Participate in Clinical Research. Archives of Internal Medicine, 2008, 168, 1294.	3.8	69
20	WHAT SHOULD RESEARCH PARTICIPANTS UNDERSTAND TO UNDERSTAND THEY ARE PARTICIPANTS IN RESEARCH?. Bioethics, 2008, 22, 203-208.	1.4	67
21	PROTECTING COMMUNITIES IN HEALTH RESEARCH FROM EXPLOITATION. Bioethics, 2006, 20, 248-253.	1.4	65
22	Systematic Review: Individuals' Goals for Surrogate Decisionâ€Making. Journal of the American Geriatrics Society, 2012, 60, 884-895.	2.6	65
23	Children's and Their Parents' Views on Facing Research Risks for the Benefit of Others. JAMA Pediatrics, 2008, 162, 9.	3.0	58
24	Quantifying the risks of non-oncology phase I research in healthy volunteers: meta-analysis of phase I studies. BMJ, The, 2015, 350, h3271-h3271.	6.0	56
25	Can We Ensure That All Research Subjects Give Valid Consent?. Archives of Internal Medicine, 2004, 164, 2201.	3.8	49
26	Considerations in the evaluation and determination of minimal risk in pragmatic clinical trials. Clinical Trials, 2015, 12, 485-493.	1.6	49
27	Pragmatic Randomized Trials Without Standard Informed Consent?. Annals of Internal Medicine, 2015, 163, 356-364.	3.9	45
28	Risks of phase I research with healthy participants: A systematic review. Clinical Trials, 2016, 13, 149-160.	1.6	43
29	Can We Improve Treatment Decision-Making for Incapacitated Patients?. Hastings Center Report, 2010, 40, 36-45.	1.0	42
30	Use of a Patient Preference Predictor to Help Make Medical Decisions for Incapacitated Patients. Journal of Medicine and Philosophy, 2014, 39, 104-129.	0.8	42
31	Quality of Parental Consent in a Ugandan Malaria Study. American Journal of Public Health, 2005, 95, 1184-1189.	2.7	41
32	Are physicians obligated always to act in the patient's best interests?. Journal of Medical Ethics, 2010, 36, 66-70.	1.8	41
33	Assent in Research: The Voices of Adolescents. Journal of Adolescent Health, 2014, 54, 515-520.	2.5	41
34	COVID-19 vaccine trial ethics once we have efficacious vaccines. Science, 2020, 370, 1277-1279.	12.6	41
35	Views of Adolescents and Parents on Pediatric Research Without the Potential for Clinical Benefit. Pediatrics, 2012, 130, 692-699.	2.1	39
36	Protecting Subjects Who Cannot Give Consent: Toward a Better Standard for " Minimal " Risks. Hastings Center Report, 2005, 35, 37-43.	1.0	38

#	Article	IF	CITATIONS
37	How do Children and Parents Make Decisions About Pediatric Clinical Research?. Journal of Pediatric Hematology/Oncology, 2008, 30, 823-828.	0.6	37
38	What is a "Minor―Increase over Minimal Risk?. Journal of Pediatrics, 2005, 147, 575-578.	1.8	36
39	Broad versus Blanket Consent for Research with Human Biological Samples. Hastings Center Report, 2013, 43, 3-4.	1.0	36
40	Does Random Treatment Assignment Cause Harm to Research Participants?. PLoS Medicine, 2006, 3, e188.	8.4	35
41	How Should Treatment Decisions Be Made for Incapacitated Patients, and Why?. PLoS Medicine, 2007, 4, e35.	8.4	34
42	Confronting Ethical and Regulatory Challenges of Emergency Care Research With Conscious Patients. Annals of Emergency Medicine, 2016, 67, 538-545.	0.6	33
43	Broad Consent for Research on Biospecimens: The Views of Actual Donors at Four U.S. Medical Centers. Journal of Empirical Research on Human Research Ethics, 2018, 13, 115-124.	1.3	31
44	One-Time General Consent for Research on Biological Samples. Archives of Internal Medicine, 2006, 166, 1449.	3.8	30
45	Risk-benefit assessment in medical research-critical review and open questions. Law, Probability and Risk, 2010, 9, 151-177.	2.4	30
46	A New Justification for Pediatric Research Without the Potential for Clinical Benefit. American Journal of Bioethics, 2012, 12, 23-31.	0.9	30
47	Minimal risk in pediatric research. Journal of Pediatrics, 2006, 149, 855-861.	1.8	27
48	Clarifying substituted judgement: the endorsed life approach: TableÂ1. Journal of Medical Ethics, 2015, 41, 723-730.	1.8	27
49	WHICH BENEFITS OF RESEARCH PARTICIPATION COUNT AS †DIRECT'?. Bioethics, 2012, 26, 60-67.	1.4	25
50	Protections for clinical trials in low and middle income countries need strengthening not weakening. BMJ, The, 2014, 349, g4254-g4254.	6.0	25
51	What Should Be Disclosed to Research Participants?. American Journal of Bioethics, 2013, 13, 3-8.	0.9	24
52	"Targeted" Consent for Pragmatic Clinical Trials. Journal of General Internal Medicine, 2015, 30, 679-682.	2.6	24
53	Is There a Role for Assent or Dissent in Animal Research?. Cambridge Quarterly of Healthcare Ethics, 2015, 24, 459-472.	0.8	23
54	What Research with Stored Samples Teaches Us About Research with Human Subjects. Bioethics, 2002, 16, 33-54.	1.4	22

#	Article	IF	CITATIONS
55	Risk Standards for Pediatric Research: Rethinking the Grimes Ruling. Kennedy Institute of Ethics Journal, 2004, 14, 187-198.	0.5	22
56	A Standard for Assessing the Risks of Pediatric Research: Pro and Con. Journal of Pediatrics, 2007, 150, 579-582.	1.8	22
57	Minimal Risk in Pediatric Research as a Function of Age. JAMA Pediatrics, 2009, 163, 115.	3.0	22
58	Treatment Decision Making for Incapacitated Patients: Is Development and Use of a Patient Preference Predictor Feasible?. Journal of Medicine and Philosophy, 2014, 39, 130-152.	0.8	22
59	Clinical research: Should patients pay to play?. Science Translational Medicine, 2015, 7, 298ps16.	12.4	22
60	Research on stored biological samples: the views of Ugandans. IRB: Ethics & Human Research, 2005, 27, 1-5.	0.8	21
61	Protecting subjects who cannot give consent: toward a better standard for "minimal" risks. Hastings Center Report, 2005, 35, 37-43.	1.0	21
62	The Theory and Practice of Surrogate Decision-Making. Hastings Center Report, 2017, 47, 29-31.	1.0	20
63	Should protections for research with humans who cannot consent apply to research with nonhuman primates?. Theoretical Medicine and Bioethics, 2014, 35, 157-173.	0.8	19
64	The potential exploitation of research participants in high income countries who lack access to health care. British Journal of Clinical Pharmacology, 2016, 81, 857-864.	2.4	19
65	How does the collection of genetic test results affect research participants?. American Journal of Medical Genetics, Part A, 2007, 143A, 1733-1738.	1.2	18
66	Is it Possible to Protect Pediatric Research Subjects without Blocking Appropriate Research?. Journal of Pediatrics, 2008, 152, 467-470.	1.8	18
67	A new method for making treatment decisions for incapacitated patients: what do patients think about the use of a patient preference predictor?. Journal of Medical Ethics, 2016, 42, 235-241.	1.8	18
68	Must Research Participants Understand Randomization?. American Journal of Bioethics, 2009, 9, 3-8.	0.9	17
69	Enrolling Minors in COVID-19 Vaccine Trials. Pediatrics, 2021, 147, .	2.1	17
70	Patients' priorities for treatment decision making during periods of incapacity: quantitative survey. Palliative and Supportive Care, 2015, 13, 1165-1183.	1.0	16
71	Issues and Challenges Associated with Data-Sharing in LMICs: Perspectives of Researchers in Thailand. American Journal of Tropical Medicine and Hygiene, 2020, 103, 528-536.	1.4	15
72	How to Enroll Participants in Research Ethically. JAMA - Journal of the American Medical Association, 2011, 305, 1587.	7.4	14

#	Article	IF	CITATIONS
73	Benefits and Burdens of Participation in a Longitudinal Clinical Trial. Journal of Empirical Research on Human Research Ethics, 2009, 4, 89-97.	1.3	13
74	Targeted Consent for Research on Standard of Care Interventions in the Emergency Setting. Critical Care Medicine, 2017, 45, e105-e110.	0.9	13
75	The ethics of peer review in bioethics. Journal of Medical Ethics, 2014, 40, 697-701.	1.8	12
76	Reconsidering the Need for Reconsent at 18. Pediatrics, 2018, 142, .	2.1	12
77	Autonomy-based criticisms of the patient preference predictor. Journal of Medical Ethics, 2021, , medethics-2021-107629.	1.8	12
78	Shared medical decisionâ€making: considering what options to present based on an ethical analysis of the treatment of brain tumors in very young children. Pediatric Blood and Cancer, 2012, 59, 216-220.	1.5	11
79	Do patients want their families or their doctors to make treatment decisions in the event of incapacity, and why?. AJOB Empirical Bioethics, 2016, 7, 251-259.	1.6	11
80	Research Involving Wards of the State: Protecting Particularly Vulnerable Children. Journal of Pediatrics, 2008, 152, 9-14.	1.8	10
81	The ethics of sham invasive intervention trials. Clinical Trials, 2009, 6, 401-402.	1.6	9
82	Contrasting Views of Risk Perception and Influence of Financial Compensation Between Adolescent Research Participants and Their Parents. Journal of Empirical Research on Human Research Ethics, 2015, 10, 49-58.	1.3	9
83	Ensuring Respect for Human Research Participants. JAMA - Journal of the American Medical Association, 2016, 316, 1149.	7.4	9
84	Public preferences on written informed consent for lowâ€risk pragmatic clinical trials in Spain. British Journal of Clinical Pharmacology, 2017, 83, 1921-1931.	2.4	9
85	A pragmatic analysis of vulnerability in clinical research. Bioethics, 2017, 31, 515-525.	1.4	9
86	Why we need legal standards for pediatric research. Journal of Pediatrics, 2004, 144, 150-153.	1.8	8
87	Three Steps to Protecting Pediatric Research Participants from Excessive Risks. PLOS Clinical Trials, 2006, 1, e25.	3.5	8
88	Assessing the Ethical and Practical Wisdom of Surrogate Consent for Living Organ Donation. JAMA - Journal of the American Medical Association, 2004, 291, 732.	7.4	7
89	What we worry about when we worry about the ethics of clinical research. Theoretical Medicine and Bioethics, 2011, 32, 161-180.	0.8	7
90	Involving Communities in Deciding What Benefits They Receive in Multinational Research. Journal of Medicine and Philosophy, 2015, 40, 584-600.	0.8	7

#	Article	IF	CITATIONS
91	Patients' beliefs regarding informed consent for low-risk pragmatic trials. BMC Medical Research Methodology, 2017, 17, 145.	3.1	7
92	A Response to Commentators on "Should Children Decide Whether They Are Enrolled in Nonbeneficial Research?". American Journal of Bioethics, 2003, 3, 37-38.	0.9	6
93	Taking the measure of the therapeutic misconception. Clinical Trials, 2012, 9, 762-764.	1.6	6
94	When clinical care is like research: the need for review and consent. Theoretical Medicine and Bioethics, 2016, 37, 193-209.	0.8	6
95	Using mobile location data in biomedical research while preserving privacy. Journal of the American Medical Informatics Association: JAMIA, 2018, 25, 1402-1406.	4.4	6
96	Innovative approaches to informed consent for randomized clinical trials: Identifying the ethical challenges. Clinical Trials, 2018, 15, 17-20.	1.6	5
97	Innovative treatment as a precursor to clinical research. Journal of Clinical Investigation, 2021, 131, .	8.2	5
98	Do U.S. regulations allow more than minor increase over minimal risk pediatric research? Should they?. IRB: Ethics & Human Research, 2013, 35, 1-8.	0.8	5
99	Surrogate Perspectives on Patient Preference Predictors: Good Idea, but I Should Decide How They Are Used. AJOB Empirical Bioethics, 2022, 13, 125-135.	1.6	5
100	Nonbeneficial Research with Individuals Who Cannot Consent: Is It Ethically Better to Enroll Healthy or Affected Individuals?. IRB: Ethics & Human Research, 2003, 25, 1.	0.8	4
101	Understanding preferences regarding consent for pragmatic trials in acute care. Clinical Trials, 2018, 15, 567-578.	1.6	4
102	Conducting human challenge studies in LMICs: AÂsurvey of researchers and ethics committee members in Thailand. PLoS ONE, 2019, 14, e0223619.	2.5	4
103	The Value in Doing Something. Critical Care Medicine, 2019, 47, 149-151.	0.9	4
104	Avoiding exploitation in multinational covid-19 vaccine trials. BMJ, The, 2021, 372, n541.	6.0	4
105	Do the Potential Medical Benefits of Phase 1 Pediatric Oncology Trials Justify the Risks? Views of the United States Public. Journal of Pediatrics, 2021, 238, 249-258.e3.	1.8	4
106	Patients' Priorities for Surrogate Decision-Making: Possible Influence of Misinformed Beliefs. AJOB Empirical Bioethics, 2022, 13, 137-151.	1.6	4
107	Promoting the Values for Surrogate Decision-making. JAMA - Journal of the American Medical Association, 2022, 328, 243.	7.4	4
108	PLACEBO RESEARCH AND THE SPIRIT OF INFORMED CONSENT. Psychosomatic Medicine, 2005, 67, 678.	2.0	3

#	Article	lF	CITATIONS
109	The Duty to Take Rescue Precautions. Journal of Applied Philosophy, 2016, 33, 240-258.	1.0	3
110	Adolescent research participants' descriptions of medical research. AJOB Empirical Bioethics, 2016, 7, 1-7.	1.6	3
111	Comparative effectiveness research: what to do when experts disagree about risks. BMC Medical Ethics, 2017, 18, 42.	2.4	3
112	Ethical issues in denial of church wedding based on couple's hemoglobin genotype in Enugu, south eastern Nigeria. BMC Medical Ethics, 2019, 20, 37.	2.4	3
113	The Potential Benefits of Research May Justify Certain Research Risks. Pediatrics, 2019, 143, .	2.1	3
114	When and how to include vulnerable subjects in clinical trials. Clinical Trials, 2020, 17, 696-702.	1.6	3
115	A Call for a Patient Preference Predictor. Critical Care Medicine, 2021, 49, 877-880.	0.9	3
116	Does it matter whether investigators intend to benefit research subjects?. Kennedy Institute of Ethics Journal, 2010, 20, 353-70.	0.5	3
117	Acceptable Risks in Pediatric Research: Views of the US Public. Pediatrics, 2022, 149, .	2.1	3
118	Overcoming language barriers in medical care. Pediatric Blood and Cancer, 2006, 47, 747-747.	1.5	2
119	Interpretation of the Subjects' Condition Requirement: A Legal Perspective. Journal of Law, Medicine and Ethics, 2010, 38, 365-373.	0.9	2
120	Resources, methods, and data infrastructure to promote research in dementia care, caregiving, and services. Journal of the American Geriatrics Society, 2021, 69, 1793-1800.	2.6	2
121	Research involving pediatric stem cell donors: A way forward. Clinical Trials, 2016, 13, 304-310.	1.6	1
122	Is it important to disclose how treatments are selected in clinical research and clinical care?. AJOB Empirical Bioethics, 2017, 8, 170-177.	1.6	1
123	Maximizing the value of human biospecimens: Lessons from coronavirus and the Seattle flu study. American Journal of Medical Genetics, Part A, 2020, 182, 2826-2828.	1.2	1
124	The Ethics of Mandatory Retention of Clinical Biospecimens for Research. Journal of General Internal Medicine, 2021, 36, 2818-2819.	2.6	1
125	Ethics of informationâ€gathering interventions in innovative practice. Internal Medicine Journal, 2020, 50, 1583-1587.	0.8	1
126	Nonbeneficial research with individuals who cannot consent: is it ethically better to enroll healthy or affected individuals?. IRB: Ethics & Human Research, 2003, 25, 1-4.	0.8	1

#	Article	IF	CITATIONS
127	Ethical and epistemic issues in the design and conduct of pragmatic stepped-wedge cluster randomized clinical trials. Contemporary Clinical Trials, 2022, 115, 106703.	1.8	1
128	Informed Consent for Research. , 0, , 703-710.		1
129	A new ethical framework to determine acceptable risks in fetal therapy trials. Prenatal Diagnosis, 2022, 42, 962-969.	2.3	1
130	Consent, decisional capacity and guardianship in mental health research. Wellcome Open Research, 0, 7, 183.	1.8	1
131	WENDLER ET AL. RESPOND. American Journal of Public Health, 2004, 94, 2048-a-2049.	2.7	0
132	Response to Open Peer Commentaries on "Must Research Participants Understand Randomization?― American Journal of Bioethics, 2009, 9, W1-W2.	0.9	0
133	International Guidelines and Ethical Context. American Journal of Bioethics Primary Research, 2010, 1, 28-30.	1.5	0
134	Justice and Nontherapeutic Pediatric Research. American Journal of Bioethics, 2014, 14, 13-15.	0.9	0
135	Which Alternatives Should Investigators Disclose to Research Subjects?. American Journal of Bioethics, 2014, 14, 54-55.	0.9	0
136	Addressing exploitation of poor clinical trial participants in North America and the European Union. European Journal of Internal Medicine, 2016, 34, e37-e38.	2.2	0
137	Is the French clinical trials regulation discriminatory?. European Journal of Internal Medicine, 2016, 34, e35-e36.	2.2	0
138	The Potential for Infrastructure Benefits and the Responsiveness Requirement. American Journal of Bioethics, 2016, 16, 1-2.	0.9	0
139	A Test of â€ ⁻ Utilitarianism for Animals, Kantianism for People'. Journal of Moral Philosophy, 2021, 18, 1-27.	0.4	0
140	Views of IRB members regarding phase 1 pediatric oncology trials. Pediatric Hematology and Oncology, 2022, , 1 -12.	0.8	0